Comparison of staging systems to predict survival in hepatocellular carcinoma

Liver International

Volumn 26, Issue 6, 2006, Pages 673-679

  Pascual, Sonia ^a   Zapater, Pedro ^a   Such, José ^a   García Herola, Antonio ^a   Sempere, Laura ^a   Irurzun, Javier ^a   Palazón, José Marí ^a   Carnicer, Fernando ^a   Pérez Mateo, Miguel ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Hepatocellular carcinoma; Prognosis; Staging system

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MODEL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; SCORING SYSTEM; STATISTICAL MODEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 33745594286     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01282.x     Document Type: Article

References (37)

1. Llovet J M, Beaugrand M. Hepatocellular carcinoma: Present status and future prospects. J Hepatol 2003; 38: S136-S149.
2. Befeler A S, Di Bisceglie A M. Hepatocellular carcinoma: Diagnosis and treatment. Gastroenterology 2002; 122: 1609-91.
3. Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1.
4. Bruix J, Sherman M, Llovet J M, et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-30.
5. Henderson J M, Sherman M, Tavill A, et al. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: Consensus statement. HPB 2003; 5: 243-50.
6. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-2.
7. Manghisi G, Elba S, Mossa A, et al. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
8. Chevret S, Trinchet J C, for the Groupe dÈtude et de Traitement du Carcinoma Hépatocellulaire et al. A new classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999; 31: 133-41.
9. Llovet J M, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
10. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: Prognostic features and survival. Gut 2001; 48: 103-9.
11. Leung T W, Tang A M, Zee B, et al. Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda Staging System and the Cancer of the Liver Italian Program Staging System. Cancer 2002; 94: 1760-9.
12. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP): Its value and limitations and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-15.
13. Tateishi R, Yoshida H, Shiina S, et al. Proposal of a new prognostic model for hepatocellular carcinoma: An analysis of 403 patients. Gut 2005; 54: 419-25.
14. The Cancer of the Liver Italian Program Investigators. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and the hepatocelular carcinoma. Hepatology 2000; 31: 840-5.
15. Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new Western prognostic system (CLIP Score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001; 34: 529-34.
16. Cillo U, Basanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: Which is the best tool available? J Hepatol 2004; 40: 124-31.
17. Kudo M, Chung H, Haji S, et al. Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: The JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-405.
18. Grieco A, Pompili M, Camitini G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: Comparison of Okuda, CLIP, and BCLC staging system in a single Italian centre. Gut 2005; 54: 411-8.
19. Malinchoc M, Kamath P S, Gordon F D, Peine C J, Rank J, Borg P C. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
20. Kamath P S, Wiesner R H, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
21. Botta F, Gianninni E, Romagnoli P, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: A European study. Gut 2003; 52: 134-9.
22. Chalasani N, Kahi C, Francois F, Pinto A, Marathe A. Model for End-Stage Liver Disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology 2002; 35: 1282-4.
23. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
24. Heuman D M, Mihas A A. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: One more positive answer. Gastroenterology 2003; 125: 992-3.
25. Gianninni E, Botta F, Testa R. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: One more positive answer. Gastroenterology 2003; 125: 993-4.
26. Marsch J W, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: Are we sure? Liver Transplant 2003; 9: 693-6.
27. Durand F, Belghiti J. Liver transplantation for hepatocelular carcinoma: should we push the limits. Liver Transplant 2003; 9: 697-700.
28. Bruix J, Fuster J, Llovet J M. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transplant 2003; 9: 701-2.
29. Yao F Y, Bass N M, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transplant 2003; 9: 684-92.
30. Sharma P, Balan V, Hernández J L, et al. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transplant 2004; 10: 36-41.
31. United Network for Organ Sharing. Policy 3.6. Allocation of livers. Available at: http://www.unos.org/PoliciesandBylaws/policies/pdfs/ policy_8.pdf
32. Pugh R N, Murray-Lyon I M, Dawson J L, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
33. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
34. Olthoff K m, Brown R S Jr, Delmonico F L, et al. Summary report of national conference: Evolving concepts in liver allocation in the MELD and PELD era. Liver Transplant 2004; 10: A6-A22.
35. Levy I, Sherman M the Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: Assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50: 881-5.
36. Marrero J A, Fontana R J, Barrat A, et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American Cohort. Hepatology 2005; 41: 707-16.
37. Testa R, Testa E, Giannini E, et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: Role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther 2003; 17: 1563-9.